Immatics Biotechnologies GmbH has reported new data from a Phase 2 study of its experimental vaccine for advanced colorectal cancer which showed that patients survived longer compared with a matched cohort from a larger UK Medical Research Council-supported study (COIN). The data were presented on 1 June at the annual meeting of the American Society of Clinical Oncology in Chicago.
